Published Paper Details:

Heart defects are increasingly diagnosed nowadays. There is a variety of heart diseases, each with its own causes, symptoms, and treatments, including congenital heart diseases such as atrial septal defect (ASD) and ventricular septal defect (VSD). The next-generation closure device for interventional treatment of congenital heart disease is considered to be bioresorbable. Bioresorbable occluders are indeed becoming more significant in percutaneous coronary interventions (PCIs) due to their unique advantages. The numerous benefits of this type of occluder make it of interest for commercialization. This study focuses on the in-vitro assessment of a bioresorbable occluder for atrial septal defects (ASDs). The study spanned two years and was conducted under real-time in-vitro degradation conditions. The degradation process included the use of phosphate buffer as an in-vitro degradation solution due to its specific characteristics. The entire in-vitro process was observed, from the sterilization of the phosphate-buffered saline (PBS) to the deployment of the occluder, until the occluder completely dissolved into the surrounding medium. The evaluation of study is based on the visual observation on the specific time durations.